Turofexorate isopropyl, also known as XL335, WAY-362450 or WAY362450, is a medication used in the treatment of non-alcoholic steatohepatitis (NASH). It has gained attention in recent years due to its potential therapeutic benefits in reducing liver inflammation and improving liver function.
Introduce this product: Turofexorate isopropyl is a selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that plays a critical role in the regulation of bile acid metabolism and lipid homeostasis. By activating FXR, Turofexorate isopropyl can reduce liver inflammation and improve liver function.
Chemical name: The chemical name of Turofexorate isopropyl is 2-(4-isopropoxyphenyl)-3-(3-chlorophenyl)propanoic acid.
Molecular formula: The molecular formula of Turofexorate isopropyl is C18H19ClO3.
Formula weight: The formula weight of Turofexorate isopropyl is 318.8 g/mol.
CAS No: The CAS number of Turofexorate isopropyl is 629664-81-9.
Top ten keywords from Google and Synonyms:
- Non-alcoholic steatohepatitis
- Liver inflammation
- Farnesoid X receptor
- Lipid homeostasis
- Bile acid metabolism
- Selective agonist
- Pharmaceutical compound
Synonyms for Turofexorate isopropyl include XL335, WAY-362450, and WAY362450.
Health benefits of this product: Turofexorate isopropyl has the potential to provide numerous health benefits in the treatment of NASH. By activating FXR, it can reduce liver inflammation and improve liver function. This can lead to improved liver health and a reduced risk of liver-related complications.
Potential effects: The potential effects of Turofexorate isopropyl are vast and varied. Its ability to selectively activate FXR makes it a promising candidate for the treatment of NASH. Additionally, Turofexorate isopropyl has shown promise in combination with other medications in improving treatment outcomes.
Product mechanism: Turofexorate isopropyl works by selectively activating FXR, a nuclear receptor that plays a critical role in the regulation of bile acid metabolism and lipid homeostasis. By activating FXR, Turofexorate isopropyl can reduce liver inflammation and improve liver function.
Safety: Turofexorate isopropyl has undergone extensive clinical trials and has been found to be safe and effective in the treatment of NASH. However, as with any medication, there is always some risk of side effects, and it is essential to consult a healthcare professional before starting any new medication or treatment regimen.
Side effects: Some potential side effects of Turofexorate isopropyl may include diarrhea, headaches, and dizziness. Additionally, there is a potential risk of liver toxicity, so regular monitoring of liver function tests is necessary during treatment.
Dosing information: The dosing of Turofexorate isopropyl will vary depending on the individual patient's medical condition, age, weight, and other factors. It is essential to follow the recommended dosing instructions provided by a healthcare professional, as taking too much or too little can affect its effectiveness and safety.
Conclusion: In conclusion, Turofexorate isopropyl shows significant potential in treating NASH. As a selective agonist of FXR, it provides greater specificity and fewer side effects than non-selective treatments. However, more research is needed to confirm its efficacy and safety in treating other medical conditions. It is essential to consult a healthcare professional before starting any new medication or treatment regimen